跳至主要内容
临床试验/JPRN-UMIN000022048
JPRN-UMIN000022048已完成未知

The prospective study to evaluate the efficacy of the combination therapy of inhaled budesonide/formoterol fumarate, clarithromycin, and montelukast in AFO after allogeneic SCT - Chiba AFO-01 study

Department of Hematology, Chiba University Hospital0 个研究点目标入组 85 人开始时间: 2016年4月25日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
85

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16years-old 至 70years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Known history of intolerance or allergy to any triplet component. 2. The patient who has past history of asthma and had attack within one year. 3. The patient who has already been treated with the triplet combination. 4. The patient who has active infection 5. The patient who has mental disability requiring treatment 6. The patient who has severe thromboembolism, including myocardial infarction, cerebral infarction, and cardiovascular complications. 7. The patient who has uncontrollable diabetes mellitus and metabolic disease 8. The patient who has other malignancy requiring anticancer treatment 9. Pregnancy or nursing. 10. At the time of enrollment as judged by the enrolling investigator would interfere with the subjects ability to comply with the study requirements

研究者

发起方
Department of Hematology, Chiba University Hospital

相似试验